Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know

Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗

November 24, 2025

Via MarketBeat

November 24, 2025

A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Topics Economy

1 Small-Cap Stock with Exciting Potential and 2 We Avoid

November 23, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

MarketBeat Week in Review – 11/17 - 11/21 ↗

November 22, 2025

Via MarketBeat

2 Cash-Heavy Stocks with Competitive Advantages and 1 We Find Risky

November 21, 2025

KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds

November 20, 2025

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a...

Via MarketMinute

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Ready For A Rebound? Here Are 10 Oversold Stocks To Watch ↗

November 17, 2025

Via Benzinga

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

November 17, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4.9% in the afternoon session after news of increased competition in the weight-loss drug market overshadowed the company’s own positive...

Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from the company.

What's Going On With Hims & Hers Health Shares Monday? ↗

November 17, 2025

Via Benzinga

Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock ↗

November 17, 2025

The latest buyback program follows a $100 million share buyback program in July 2024, which has now been completed.

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization

November 17, 2025

From Hims & Hers

Via Business Wire

November 17, 2025

From Hims & Hers

Via Business Wire

Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing ↗

November 14, 2025

Hims & Hers launches Labs, offering annual biomarker testing plans with doctor-developed guidance and expanded diagnostics planned across key health categories.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds

November 13, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and...

Hims & Hers Stock Logs 3-Day Losing Streak As Truist Calls Out Klarna GLP-1 Changes — Retail Sees Fresh Buy Zone ↗

Topics Stocks

November 13, 2025

Truist pointed to updated GLP-1 intake features, including Klarna financing, shorter shipping intervals and new semaglutide microdosing options.

Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗

November 13, 2025

Via Benzinga

Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys

November 13, 2025

From Hims & Hers

Via Business Wire

2 Strong Healthcare Stock Picks for Growth Investors ↗

November 13, 2025

If you're a growth-oriented stock buyer, there are plenty of options in the healthcare space.

2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors ↗

November 13, 2025

Healthcare stocks have plenty to offer new investors.

All four of these stocks have big upside.

Huge Opportunity to Buy These 4 Stocks ↗

November 12, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare technology stocks fared in Q3, starting with Hims...

Healthcare Technology Stocks Q3 Teardown: Hims & Hers Health (NYSE:HIMS) Vs The Rest

November 11, 2025

Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants ↗

November 11, 2025

Although Hims & Hers Health has tanked in the past month, the quantitative profile suggests a contrarian trade is brewing for HIMS stock.

Via Benzinga

Hims & Hers Health’s Q3 Earnings Call: Our Top 5 Analyst Questions

November 10, 2025

Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth driven by surging demand for personalized care, new specialty launches, and...

The company continues to have a strong growth outlook ahead.

Topics Earnings

Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? ↗

November 09, 2025

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.